Sriskandarajah, Priya

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 78

Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment

Pawlyn, C., Khan, M. S., Muls, A., Sriskandarajah, P., Kaiser, M. F., Davies, F. E., Morgan, G. J., & Andreyev, H. J. N. (2014) · Blood

Multiple Myeloma Research and TreatmentsDrug Transport and Resistance Mechanisms

Cited by 66